Skip to main content
SpringerLink
Log in

Das Nachsorgeprinzip beim metastasierten Prostatakarzinom

Wenig Diagnostik, viel Support

The aftercare principle for metastasizing prostate cancer—little diagnostics much support

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Im Stadium des fortgeschrittenen PCA — abgesehen bei intermittierenden Strategien — befindet sich der Patient in ständiger Behandlung. Er muss zur Prüfung der Therapiewirkung engmaschig nachkontrolliert werden, damit beim Versagen der aktuellen Therapie schnellstmöglich zu einem anderen Regime gewechselt werden kann. Weil die Progression der Erkrankung in den meisten Fällen jedoch unaufhaltsam ist, besteht das Ziel der Therapie darin, die Lebensqualität des Patienten auf dem höchsten Niveau zu erhalten. Um den Patienten — wenn möglich — in seiner häuslichen Umgebung therapeutisch zu begleiten, sollten supportive Therapien eingesetzt werden, wie der Ausgleich einer Anämie oder die bedarfsangepasste Schmerzmedikation. Durch die Gabe von Bisphosphonaten kann etwaigen Skelettkomplikationen vorgebeugt werden.

Abstract

For advanced prostate cancer — not including intermittent strategies — the patient is in continual treatment. The effect of the therapy must be controlled so that its failure can be determined as soon as possible and a new regimen started. As in most cases the progression of the disease can not be stopped, the aim of the therapy is to provide the patient with the best possible quality of life. In order to carry out therapy, if possible in the patient’s usual environment, supportive therapies should be used, such as compensation for anaemia or pain therapy as required. Skeletal complications can be prophylactically treated by the use of biphosphonates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Algra PR, Bloem JL, Tissing H, Falke TH, Arndt JW, Verboom LJ (1991) Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 11(2): 219–232

    PubMed  Google Scholar 

  2. Coleman RE, Ourohit OP, Vinholes JJ, Zekri J (1997) High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80: 1652–1660

    Article  PubMed  Google Scholar 

  3. Dearnaley DP, Sydes MR, Mason MD et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO Trial). J Natl Cancer Inst 95: 1300–1311

    PubMed  Google Scholar 

  4. Diamond TH, Winters J, Smith A et al. (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 92: 1444–1450

    Article  PubMed  Google Scholar 

  5. Dunst J, Kuhnt T et al. (2003) Anaemia in cervical cancers: patterns of relapse and association with tumor hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56(3): 778–787

    Article  PubMed  Google Scholar 

  6. Dupont A, Cusan L et al. (1991) Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol 146: 1064–1067

    PubMed  Google Scholar 

  7. Ercole CJ, Lange PH et al. (1987) Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 138: 1181–1184

    PubMed  Google Scholar 

  8. Flynn DF, Shipley WU (1991) Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am 18(1): 145–152

    PubMed  Google Scholar 

  9. Frommhold H, Guttenberger R, Henke M (1998) The impact of blood haemoglobin content on the outcome of radiotherapy. Strahlenther Onkol 174 [Suppl IV]: 31–34

    Google Scholar 

  10. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98(3): 259–260

    Article  PubMed  Google Scholar 

  11. Grogan M, Thomas GM et al. (1999) The importance of maintaining high hemoglobin levels during radiation treatment of the carcinoma of the cervix. Cancer 86: 1531–1536

    Article  Google Scholar 

  12. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165: 136–140

    Article  PubMed  Google Scholar 

  13. Henke M, Laszig R, Rube C et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy : randomized, double-blind, placebo-controlled trial. Lancet 362 (9392): 1255–1260

    Article  PubMed  Google Scholar 

  14. Huddart RA, Rajan B, Law M, Meyer L, Dearnaley DP (1997) Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol 44(3): 229–236

    Article  PubMed  Google Scholar 

  15. Iacovou JW, Marks JC, Abrams PH, Gingell JC, Ball AJ (1985) Cord compression and carcinoma of the prostate: is laminectomy justified? Br J Urol 57(6): 733–736

    PubMed  Google Scholar 

  16. Kelly WK, Scher HI, Mazumdar M et al. (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607–615

    PubMed  Google Scholar 

  17. Kuban DA, El-Mahdi AM, Sigfred SV (1986) Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology 18: 364–369

    Article  Google Scholar 

  18. Leo ME, Bilhartz DL, Bergstralh, Oesterling JE (1991) Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 145: 802–806

    PubMed  Google Scholar 

  19. Lipton A, Glover D, Harvey H et al. (1994) Pamidronate in the treatment of bone metastases: results of 2 dose ranging trials in patients with breast and prostate cancer. Ann Oncol 5: S31–S35

    PubMed  Google Scholar 

  20. Lissoni P, Rovelli F et al. (2001) A Pase II study of s.c.low-dose IL2 plus Erythropoietin in metastatic renal cell carcinoma progressing on IL2 allone. Anticancer Res 21: 777–779

    PubMed  Google Scholar 

  21. Littlewood TJ, Bajetta E et al. (2001) Effects of epoetin alfa on heamatologic parameters and qualità of life in cancer patients receiving nonplatinum chemotherapy. J Clin Oncol 19: 2865–2874

    PubMed  Google Scholar 

  22. Messing EM, Thompson I Jr (2003) Follow Up of conservatively managed prostate cancer — wachtful waiting and primary hormonal therapy. Urol Clin N Am 30: 687–702

    Article  Google Scholar 

  23. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 104: 83–93

    Article  PubMed  Google Scholar 

  24. Mittelman M, Zeidman A et al. (2004) Erythropoietin has an antimyeloma effect — a hypothesis based on a clinical observation supported by animal studys. Eur J Haematol 72: 155–165

    Article  PubMed  Google Scholar 

  25. Modic MT, Masaryk T, Paushter D (1986) Magnetic resonance imaging of the spine. Radiol Clin North Am 24(2): 229–245

    PubMed  Google Scholar 

  26. Nowrousian MR (2000) Pathophysiologie der tumorbedingten oder chemotherapieinduzierten Anämie. In: Nowrousian MR (Hrsg) Supportive Therapie in der Onkologie. Zuckschwerdt, München, S 84–98

  27. Nowrousian MR (2002) Pathophysiology of cancer related anaemia. In: Nowrousian MR (ed) Recombinant Human Erythropoietin(rhEPO) in clinical oncology — scientific and clinical aspects of anaemia in cancer. Springer, Wien, pp 39–62

  28. Oefelein MG, Richuiti V, Conrad W et al. (2001) Skeletal fracture rate associated with androgen supression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724–1728

    Article  PubMed  Google Scholar 

  29. Österborg A, Brandberg Y et al. (2002) Randomized double-blind, placebo controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486–2494

    Google Scholar 

  30. Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. New Engl J Med 343: 604–610

    Article  PubMed  Google Scholar 

  31. Osborn JL, Getzenberg RH, Trump DL (1995) Spinal cord compression in prostate cancer. J Neurooncol 23: 135–147

    Article  PubMed  Google Scholar 

  32. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone refractory prostate cancer treated with single-agent chemotherapy. Cancer 70(12): 2870–2878

    PubMed  Google Scholar 

  33. Rubin H, Lome LG, Presman D (1974) Neurological manifestations of metastatic prostate carcinoma. J Urol 111: 799–802

    PubMed  Google Scholar 

  34. Rubins J (1995) Metastatic renal cell carcinoma: response to treatment with human recombinant erythropoietin. Ann Intern Med 122: 676–677

    PubMed  Google Scholar 

  35. Rudat V, Dietz A et al. (1999) Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 53: 119–125

    Article  PubMed  Google Scholar 

  36. Saad F, Gleason DM, Murray R et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458–1468

    PubMed  Google Scholar 

  37. Silver DF, Piver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer. Gynecol Oncol 73: 280–284

    Article  PubMed  Google Scholar 

  38. Smith DC, Vogelzang NJ, Goldberg HL et al. (1993) High dose cyclophosphamide (CTX) with granulocyte-macrophage stimulating factor (GM-CSF) in hormone refractory prostate carcinoma. Proc Am Soc Clin Oncol 11: 213

    Google Scholar 

  39. Smith JA Jr, Lange PH et al. (1997) Serum markers as apredictor of response duration and patients survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 157: 1329–1334

    Article  PubMed  Google Scholar 

  40. Smith MR (2002) Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21: 159–166

    Article  PubMed  Google Scholar 

  41. Smith MR, McGovern FJ, Zietman AL et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New Engl J Med 345: 989–991

    Article  PubMed  Google Scholar 

  42. Smith M et al. (2003) Randomised controlled trial of zoledronic acid to prevent boneloss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008–2012

    Article  PubMed  Google Scholar 

  43. Smith MR, Eastham J, Gleason DM et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 170: 2392–2393

    Article  Google Scholar 

  44. Stüben G, Thews O, Pottgen C et al. (2001) Recombinant Human Erythropoietin increases the radiosensitivity of xenografted human tumors in anaemic nude mice. J Cancer Res Clin Oncol 127: 346–350

    Article  PubMed  Google Scholar 

  45. Tarnawski R, Skladowski K et al. (1997) Prognostic value of hemoglobin concentration in radiotherapy for cancer of the supraglottic larynx. Int Radiat Oncol Biol Phys 38: 1007–1011

    Article  Google Scholar 

  46. Thews O, König R et al. (1998) Enhanced radiosensitivity in experimental tumors following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78: 752–56

    PubMed  Google Scholar 

  47. Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anaemia-induced reduction in cyclophosphamid toxicity in rat tumors. Cancer Res 61: 1358–1361

    PubMed  Google Scholar 

  48. Werner-Wasik M, Scott C, Cox JD et al. (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patient swith locally advanced non-small-cell-lung cancer (LA-NSCLC): identification of 5 groups with different survival. Int Radiat Oncol Biol Phys 48: 1475–1482

    Article  Google Scholar 

  49. Yao Siu-Long, DiPaola RS (2003) An evidence-based approach to prostate cancer follow-up. Semin Oncol 30(3): 390–400

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik, Caritaskrankenhaus, Bad Mergentheim

    K. Heine &  J. M. Wolff

  2. Urologische Klinik, Caritaskrankenhaus, Uhlandstr. 7, 97980, Bad Mergentheim

    J. M. Wolff

Authors
  1. K. Heine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Wolff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heine, K., Wolff, J.M. Das Nachsorgeprinzip beim metastasierten Prostatakarzinom . Urologe 44, 1009–1017 (2005). https://doi.org/10.1007/s00120-005-0885-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-005-0885-6

Schlüsselwörter

Keywords

Search

Navigation